Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Cognitive Impairment Associated with Schizophrenia (CIAS) pipeline market research report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated with Schizophrenia (CIAS) and features dormant and discontinued projects.
What are the key targets in the CIAS pipeline market?
The key targets in the CIAS pipeline market are Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium and Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA. Glutamate Ionotropic Receptor NMDA Type Subunit has the highest number of pipeline products.
CIAS pipeline market, by target
For more target insights, download a free report sample
What are the key MoA in the CIAS pipeline market?
The key MoA in the CIAS pipeline market are Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist. Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist has the highest number of pipeline products in the CIAS pipeline market.
CIAS pipeline market, by MoA
For more MoA insights, download a free report sample
What are the key RoA in the CIAS pipeline market?
The key RoA in the CIAS pipeline market are Oral and Nasal. Oral has the highest number of pipeline products in the the CIAS pipeline market.
CIAS pipeline market, by RoA
For more RoA insights, download a free report sample
What are the key molecule type in the CIAS pipeline market?
The key molecule type in the CIAS pipeline market are Small Molecule and Synthetic Peptide. Small molecule has the highest number of pipeline products in the CIAS market.
CIAS pipeline market, by molecule type
For more molecule type insights, download a free report sample
What are the key companies in the CIAS pipeline market?
The key companies in the CIAS pipeline market are Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV. Autifony Therapeutics Ltd has the highest number of pipeline products in the CIAS pipeline market.
CIAS pipeline market, by companies
To know more about companies, download a free report sample
Market report overview
Key targets | Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium And Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA |
Key MoA | Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist |
Key RoA | Oral and Nasal |
Key Molecule Type | Small Molecule and Synthetic Peptide |
Key companies | Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Astellas Pharma Inc
AstraZeneca Plc
Atai Life Sciences NV
Autifony Therapeutics Ltd
Biogen Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Coronis NeuroSciences Ltd
Cyclerion Therapeutics Inc
EuMentis Therapeutics Inc
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Monument Therapeutics Ltd
Neurocrine Biosciences Inc
Novartis AG
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Spherium Biomed SL
Suven Life Sciences Ltd
Vanda Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the CIAS pipeline market?
The key targets in the CIAS pipeline market are Glutamate Ionotropic Receptor NMDA Type Subunit, Neuronal Acetylcholine Receptor Subunit Alpha 7, Potassium Voltage Gated Channel Subfamily C Member 1, Cholinergic Receptor Muscarinic, Sodium And Chloride Dependent Glycine Transporter 1, 5-Hydroxytryptamine Receptor 4, 5-Hydroxytryptamine Receptor 5A, Catechol O Methyltransferase, D Amino Acid Oxidase, and Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA.
-
What are the key MoA in the CIAS pipeline market?
The key MoA in the CIAS pipeline market are Neuronal Acetylcholine Receptor Subunit Alpha 7 Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor, 5-Hydroxytryptamine Receptor 4 Agonist, 5-Hydroxytryptamine Receptor 5A Antagonist, Catechol O Methyltransferase Inhibitor, Cholinergic Receptor Muscarinic Agonist, D Amino Acid Oxidase Inhibitor, Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABAAntagonist, and Gamma-Aminobutyric Acid Type B Receptor Subunit (Gamma Aminobutyric Acid Agonist.
-
What are the key RoA in the CIAS pipeline market?
The key RoA in the CIAS pipeline market are Oral and Nasal.
-
What are the key molecule type in the CIAS pipeline market?
The key molecule type in the CIAS pipeline market are Small Molecule and Synthetic Peptide. Small molecule has the highest number of pipeline products in the CIAS market.
-
What are the key companies in the CIAS pipeline market?
The key companies in the CIAS pipeline market are Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, and Atai Life Sciences NV.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.